VANCOUVER, May 15 /PRNewswire-FirstCall/ - Biotech Holdings reports that sales of its Sucanon diabetes drug for the quarter ended March 31, 2007 were $150,761. This was an increase of $23,567 or about 18.5% over the revenues of the quarter ending December 31, 2006 and an increase of $122,526 or approximately 400% over revenues of $28,235 in the year-earlier quarter ending March 31, 2006.
The quarter ended March 31, 2007 was the second consecutive quarter of sales growth. To support this growth, the Company added an additional manager to its Mexico City office in January, 2007.
All figures are subject to confirmation in the issuance of the Company's audited annual financial statements, including the March 31, 2007 quarter, which are projected to be made available and filed to sedar.com in the Company's second fiscal quarter, ending September 30, 2007.
For further information, contact Austin Rand at Biotech Holdings, 1 888 216 111 (toll-free) 8a.m. to 4 p.m. Pacific time. For background information on Biotech Holdings, or to receive news updates, see www.biotechltd.com.
This release has been approved by the Board of Directors of Biotech Holdings. Directors of the Company can be reached through the Company's main telephone number, 604 295 1119.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
Robert B. Rieveley, Pres.
On behalf of the Board of Directors
Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management's best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed.
CONTACT: Austin Rand at Biotech Holdings, 1-888-216-111 (toll-free)
Biotech Holdings Ltd.